This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Last Chance! Online Registration Closes in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 13 - 16, 2023
Marriott Marquis San DiegoLive In-Person Event: December 13 - 16, 2023
Book Now
Menu
Register
keyboard_arrow_right

MAIN CONFERENCE DEC. 15 - PST/PDT (Pacific Daylight, GMT-7)

keyboard_arrow_leftSearch & Filter
search

MAIN CONFERENCE DEC. 15 - PST/PDT (Pacific Daylight, GMT-7)

search
6:30am - 7:15am
Sunrise Yoga: Wellness Event
7:15am - 7:30am
Registration
Showing 2 of 2 Streams
7:30am - 8:00am
Faster Process of Antibody Sequence Development to Impact Drug Development with AI Technology
  • Kane Qi - Chief Commercial Officer, Great Bay Bio
7:30am - 8:00am
Integrated Discovery and Functional Testing of Novel CAR-T Constructs Targeting Peptide/MHC Complexes
  • William Carson IV, PhD - Head of Translational Medicine, Alloy Therapeutics
Showing 2 of 2 Streams
8:10am - 8:15am
Co-Chairs’ Remarks
  • Jennifer Cochran, Ph.D. - Professor and Department Chair of Bioengineering, Stanford University
  • Jun Wang, Ph.D. - Assistant Professor, Department of Pathology, NYU Grossman School of Medicine
8:15am - 8:45am
LILRBs - Myeloid Checkpoint Targets for Cancer Treatment
  • Chengcheng (Alec) Zhang, Ph.D. - Professor, Department of Physiology, UT Southwestern Medical Center
8:45am - 9:15am
Activating Clustering-dependent Receptors through IgG Hexamers – HexaBody-CD27
  • Esther Breij, PhD - Vice President, Head of Translational Research, Genmab BV
9:15am - 9:45am
Probing Novel Immune Feedback Modulators in the Tumor Micro-environment
  • Jun Wang, Ph.D. - Assistant Professor, Department of Pathology, NYU Grossman School of Medicine
8:10am - 8:15am
Chairwoman’s Remarks
  • Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
8:15am - 8:45am
Turning Intracellular Antibodies into Biodegraders and Using Antibody Paratopes for Chemical Surrogates
  • Terry Rabbitts - Professor of Molecular Immunology, Institute of Cancer Research
8:45am - 9:15am
Engineering Proteolysis-targeting Antibodies (PROTABs) to Degrade Cell-surface Proteins
  • Wenting Tsai - Scientist 3, Genentech
9:15am - 9:45am
Development of TPD2, A Dual-precision Approach for Targeted Delivery of Targeted Protein Degraders
  • James Palacino - Vice President and Head of Biology, Orum Therapeutics
9:45am - 10:30am
Networking Refreshment Break, Exhibit and Poster Viewing
Showing 2 of 2 Streams
10:30am - 11:00am
Targeting the Novel Immune Checkpoint VISTA Using a Rational Antibody Development Strategy
  • Jerome Boyd-Kirkup, Ph.D. - Chief Scientific Officer and Co-Founder, Hummingbird Bioscience
11:00am - 11:30am
CD93 Blockade for Tumor Vascular Normalization
  • Yuwen Zhu, Ph.D. - Associate Professor, Surgical Oncology Division, University of Colorado Denver
11:30am - 12:00pm
The Perspective of STING Agonists and IL-35 Blockade in Solid Tumor Therapy
  • Sirui Li, PhD - Research Associate, Laboratory of Dr. Jenny Ting, University of North Carolina at Chapel Hill
10:30am - 11:00am
Strategies for the Treatment of Antibody-mediated Autoimmunity
  • Sally Ward, PhD - Professor and Director, University of Southampton
11:00am - 11:30am
Harnessing Modular E3 Ligase and Cytokine Receptor Targeting Chimeras to Degrade Cell-surface and Extracellular Proteins
  • Josef Gramespacher, PhD - Co-founder and Senior Scientist, EpiBiologics
11:30am - 12:00pm
Sweeping Antibody® to Maximize Therapeutic Potential in Muscle Disease Models
  • Taichi Kuramochi - Head of Biologics Discovery Department, Chugai Pharmaceutical Co., Ltd.
Showing 5 of 5 Streams
12:05pm - 12:35pm
Wrangling Diverse OmniAb Antibody Repertoires with OmniDeep
  • Bob Chen, PhD - Senior Director, Discovery Systems, OmniAb
12:05pm - 12:35pm
The Future of Plasmid Maxi-prep is Here: AmMag™ Quatro Automated Solution
  • Rouba Najjar - Head of Product Marketing, GenScript Biotech
12:05pm - 12:35pm
Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization
  • Kathrin Hammon - Account Manager, Genovac
12:05pm - 12:35pm
Democratizing Access to Broad B Cell Diversity for Rapid Monoclonal Antibody Discovery from Humans and Beyond
  • Vincent Pai - Associate Director, Product Management, Bruker Cellular Analysis
12:05pm - 12:35pm
Build Optimal Bispecifics with Speed and Precision Using Integrated Discovery, Engineering, and Antibody Assessment Technologies
  • Patrick Farber, PhD - Principal Scientist, Molecular Design & Engineering, AbCellera
12:35pm - 1:45pm
Networking Luncheon, Exhibit and Poster Viewing
Showing 5 of 5 Streams
1:45pm - 2:15pm
The BioXp® System: Accelerating Hit-to-Lead Discovery by Breaking through Critical Synthesis Bottlenecks
  • Krishna Kannan, PhD - Senior Director, Product Development, Telesis Bio
1:45pm - 2:15pm
Engineering Unique Properties in Next-Gen Antibody Therapies
  • Jordon Wang, PhD - COO and SVP of Technology Development, AvantGen
1:45pm - 2:15pm
Antibody Sequence and Structure-based Workflows for Diversity and Developability Assessments
  • Vinodh Kurella, PhD - Senior Scientist, Takeda
  • Monica Watson, PhD - Field Application Scientist, Geneious Biologics
1:45pm - 2:15pm
Designing Purification Strategies for Bispecific Antibodies Based on Molecule Design
1:45pm - 2:15pm
Efficient Therapeutic Development Using The Pfenex Expression Technology® Platform
  • Chris Warner, PhD - Associate Director, Analytical Development, Primrose Bio
Showing 2 of 2 Streams
2:25pm - 2:30pm
Co-Chairs’ Remarks
  • Shannon Turley, PhD - Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine, Genentech
  • Jo Viney, Ph.D. - Founder, President and CEO, Seismic Therapeutic
2:30pm - 3:00pm
The Application of Generative Biology to Accelerate Therapeutics for Treating Immune Mediated Diseases
  • Kristen Hopson, Ph.D. - Vice President of Preclinical Discovery and Develo, Generate Biomedicines
3:00pm - 3:30pm
A Deep Learning Pipeline for Protein Binder Design
  • Nate Bennett, Ph.D. - Postdoctoral Fellow, University of Washington
3:30pm - 4:00pm
From the Laboratory to the Clinic: Anti-TNF and Anti-IL-23 Combination Therapy in Inflammatory Bowel Disease
  • Leon Chang - Principal Scientist, Johnson & Johnson
2:25pm - 2:30pm
Chairman’s Remarks
  • Jamie Spangler, Ph.D. - Assistant Professor, Johns Hopkins University
  • Shelley Force Aldred, Ph.D. - Co-Founder & CEO, Rondo Therapeutics
2:30pm - 3:00pm
Engaging Adaptive and Innate Immune Systems with Bispecific Antibodies Targeting CD28 or CD47
  • Nicolas Fischer, Ph.D. - CEO, Light Chain Bioscience
3:00pm - 3:30pm
XTEN® Polypeptide-masked Protease Activated T Cell Engager (XPAT®): A Novel Format to Mitigate the On-Target, Off-Tumor Problem
  • Tracy Young, PhD - Director, Protein Engineering, Amunix Pharmaceuticals, Inc, a Sanofi Co
3:30pm - 4:00pm
Bispecific Immune Engagers Targeting Cancer-specific Neoantigens Created by Design
  • Shohei Koide, PhD - Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine
4:00pm - 4:45pm
Networking Refreshment Break, Exhibit and Poster Viewing
Showing 2 of 2 Streams
4:45pm - 5:15pm
Next Generation Therapies for Treating Autoimmunity and Inflammation
  • Alison Budelsky, Ph.D. - Vice President Immunology Research, Eli Lilly & Company
5:15pm - 5:45pm
Targeting Inhibitory Receptors for Controlling Inflammation
  • Steven Rust - Senior Director Protein Engineering, Gilead Sciences
5:45pm - 6:15pm
Engineering of Antibodies for Optimal FcRn Engagement
  • Maximilian Brinkhaus, PhD - Scientist, Argenx
4:45pm - 5:15pm
Targeting Multiple Activating Pathways with Natural Killer Cell Engagers
  • Katrina Bykova, PhD - Group Leader, Discovery Biology & Pharmacology, Xencor
5:15pm - 5:45pm
Improved Tolerability and Tumor Specific Delivery of a Therapeutic Bispecific T Cell Engager Using a pH-Sensitive Nanoparticle Platform
  • Tian Zhao, PhD - Vice President of R&D, OncoNano Medicine Inc.
5:45pm - 6:15pm
Progress on REV403, A Guided Antibody T cell Engager Targeting EGFR and PDL1 for Solid Tumors
  • Werner Meier - Chief Scientific Officer, Revitope Oncology
6:15pm - 7:15pm
Networking Reception, Exhibit and Poster Viewing
7:00pm-10:00pm - OmnidAb™ “Heavy Chain” Party Exclusive Event– 90’s Themed Reception ** INVITATION ONLY **
Showing 1 of 1 Streams
MAIN CONFERENCE DEC. 14
NextMAIN CONFERENCE DEC. 16
Filter
Streams
Formats
Choose Day